home / stock / mset / mset news

MSET News and Press, Madison Sports & Entmt Group Inc From 03/31/23

Stock Information
Company Name: Madison Sports & Entmt Group Inc
Stock Symbol: MSET
Market: OTC
Menu
MSET MSET Quote MSET Short MSET News MSET Articles MSET Message Board
Get MSET Alerts

News, Short Squeeze, Breakout and More Instantly...
MSET - Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

(NewsDirect) Mindset Pharma CEO James Lanthier joins Proactive's Natalie Stoberman to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery. Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state...
MSET - Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics

TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) today issued a letter to shareholders from James Lanthier, Chief Executive Officer of Mindset. Dear Fellow Shareholder...

MSET - Mindset Pharma To Defend Against Lawsuit Filed By Reunion Neurosciences

TORONTO, March 14, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat ne...

MSET - Mindset Pharma and PharmAla partnership makes first medical grade psilocybin sale in Australia

(NewsDirect) Mindset Pharma CEO James Lanthier and PharmAla CEO Nick Kadysh join Proactive's Natalie Stoberman to announce their first sale of pharmaceutical grade psilocybin into the Australian market. Lanthier and Kadysh said the psilocybin is being purchased by Reset Mind Sciences Limi...
MSET - Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin Into Growing Australian Market via Sales Partnership

TORONTO, March 06, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”) , a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat n...

MSET - Mindset Pharma Announces Grant of Options

Toronto, Ontario--(Newsfile Corp. - February 3, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that it has granted an aggregate of 6,065,000 options to purchase common shares of the Company to directors, officers and consultants of t...

MSET - Mindset Pharma Receives Another Allowance from USPTO for Patent Application Expanding Composition of Matter for Family 1 Psilocybin Analogs

TORONTO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") , a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neuro...
MSET - Mindset Pharma Receives Allowance for U.S. Patent Application Covering Composition of Matter for Its Lead Psychedelic Therapeutic Candidate, MSP-1014, And Additional Family 1 Tryptamine Prodrug Candidates

TORONTO, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") , a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neuro...

Previous 10 Next 10